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Poster Session II S345x 2 and fludarabine 25 mg/m2/d x 5 (FluCy) for NMAT.Methotrex-
ate 5 mg/m2 on days +1, +3 and +6, mycophenolate mofetil day -1 to
+60 and tacrolimus day -1 to off by +180 was the GvHD prophylaxis
regimen in 90%. Patient characteristics at NMAT included: male
(n 5 24), female (n 5 16), median (range) age 52 (21-71) yrs, KPS
90-100 (n 5 12), KPS 50-80 (n 5 28), NHL (n 5 12), AML (n 5
10), HL (n 5 8), MDS (n 5 5), ALL (n 5 2), MM (n 5 2), PLL
(n5 1),HLA-matched related donor (n5 14), 7/8HLA-mismatched
related donor (n 5 1), HLA-matched unrelated donor (n 5 15),
HLA-mismatched unrelated donor (n 5 9 at 9/10 and n 5 1 at
8/10), complete remission (CR, n 5 11), no prior CR (n 5 12), and
relapsed disease (n 5 17). Prior transplants included autologous
(N 5 19) and allogeneic (N 5 2). The TRM cumulative incidence
at Day +100 and 1-yr post NMAT was 13% (CI 1-25%) and 34%
(CI 17-51%) respectively.Overall,TRMdeathswere due to infection
(n5 8), GvHD (n5 2), regimen-related toxicity (n5 2), hemorrhage
(n5 1). OS estimates at Day +100, 1-yr, and 3-yrs post NMATwere
80% (CI 68-92%), 43% (CI 27-58%), and 19% (CI 7-32%) respec-
tively. OS was improved in patients with KPS 90-100 (1 yr OS 58%
vs. 36%, p 5 0.04) but worse in recipient/donor CMV +/- vs. other
combinations (1 yr OS 8% vs. 59%, p 5 0.001). PFS at Day +100,
1-yr, and 3-yrs was 65% (CI 50-80%), 25% (CI 12-38%), and 14%
(CI 3-25%) respectively. Patients with advanced disease, defined by
CIBMTR criteria http://www.cibmtr.org/ReferenceCenter/Slides
Reports/SummarySlides/pages/index.aspx, had Day +100 PFS 54%
(CI 24-74%) with PFS 21% (CI 6-40%) at both 1-and 2-yrs. FluCy
has a low rate ofTRMand is curative in about 1/5 of advanced disease
patients. Identification of pre-NMAT factors, which predict for long
term survival after FluCymay allow for appropriate patient selection
for FluCy versus alternative NMAT regimens.
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BOOSTER INFUSION OF T-CELL DEPLETED, CD34+ ENRICHED, DONOR
CELLS RESULTS IN SUSTAINED COUNT RECOVERY FOR PATIENTS
WITH POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL
TRANSPLANTATION
Ramsingh, G., Rettig, M., Gabriel, J., Westervelt, P., Uy, G.L.,
Abboud, C.N., DiPersio, J.F. Washington University in St. Louis, St.
Louis, MO
Poor graft function following allogeneic stem cell transplantation
(ASCT) isdefinedbycytopenias in thepresenceof completedonoren-
graftment. Infusion of unselected donor hematopoietic stem cells
(HSC) can improve cytopenias but may increase graft versus host dis-
ease (GVHD). Here we conducted a single institution prospective
study to investigate the feasibility of using ‘‘booster’’ infusions of T-
cell depleted, CD34+ enriched donor peripheral blood mononuclear
cells mobilized using G-CSF +/- plerixafor to improve the blood
counts and decrease transfusion requirements in patients with poor
graft function following ASCT. Patients age .18 years who were at
least 60 days post ASCT with persistent cytopenia (Platelets
\20,000/mm3 or ANC\500,000/mm3, transfusion dependent or in-
adequate response tohematopoietic growth factors.30days)withno
reversible etiology were included in the study. Only patients with do-
nor chimerism of$90% were included in the study. To date we have
enrolled a total of 6 patients (1 unrelated, 5 related), Age range 25-68
(mean56.5),Male: Female ratio 1:1.One relateddonorwithdrewcon-
sent after enrolling. All 5 patients had platelet counts below 20,000
/mm3 and were platelet transfusion dependent with 1 patient also re-
quiring RBC transfusions. Unrelated donor stem cell were mobilized
using standardNMDPguidelines and related usingGCSF+Plerixafor
(GCSF 10mcg/KgSC x 5 days followed by plerixafor 320mcg/Kg IV
four hour prior to mobilization). CD34+ cells were selected from the
leukapharesis product usingCliniMACS (Miltenyi) and infused to the
recipientwithout conditioning.All products contained.99%CD34+
cells with\0.01% T-cells. A median of 12.5x106 (range 3.1x106 -
23.9x106) CD34+ cells per patient were obtained. No donor or recip-
ient toxicity related to the procedure or worsening of GVHD was
observed. 4patients achieved transfusion independencewith sustained
response in 3 (follow up 7-365 days).Median time to platelet recovery
was 26 days (range 14-62). 2 patients died (1 disease relapse, 1 unex-
plained cause). This study shows the feasibility of administering
‘booster’ CD34+ selected cells fromdonor for poor graft function fol-
lowing ASCT, with minimal toxicity and durable response. A larger
study to evaluate efficacy is warranted.381
ALLOGENEIC TRANSPLANTATION IN ADULT ALL: CLINICAL EQUIPOISE
IN CANADA
Paulson, K.1, Raymond, C.2, Szwajcer, D.1, Wall, D.A.1, Seftel, M.D.1
1University of Manitoba, Winnipeg, MB, Canada; 2University of Mani-
toba, Winnipeg, MB, Canada
Introduction: Adults with acute lymphoblastic leukemia (ALL) in
first complete remission (CR1) may be treated with chemotherapy
or allogeneic hematopoietic stem cell transplantation (alloHCT).
The MRC/ECOG trial1 demonstrated a survival benefit to standard
risk patients with a matched sibling donor (MSD). However, pediat-
ric inspired chemotherapy, reduced intensity conditioning (RIC), and
alternative stem cell sources have renewed controversy about the role
of alloHCT in CR1.We hypothesized that Canadian physicians who
treat adult ALL would demonstrate wide practice variation.
Methods: Physician members of the Canadian Blood and Marrow
Transplant Group (CBMTG) and hematologists at all university-
based medical centres in Canada were contacted via email with a val-
idated electronic survey in May 2011.
Results: 69 of 173 physicians surveyed responded(40%). Themajor-
ity of respondents worked at centres that saw fewer than 20 adult
ALL patients annually. While there was high agreement with al-
loBMT in CR1 high risk cytogenetics or induction failure after a sin-
gle chemotherapy course (91.7% and 87.5%, respectively), only
45.9% and 19.3% felt that age .35 and T cell immunophenotype
would be indications for alloHCT in CR1. High WBC (.30 for
B-Cell, .100 for T-Cell) was felt to be an indication for alloHCT
by 81.2% of respondents. Respondents felt that the presence of min-
imal residual disease (MRD) was a strong indication for alloHCT
(63.8% agree), although most (66.7% agree) did not have access to
MRD testing. Most (96%) felt that a well matched unrelated donor
was an acceptable alternative to aMSD.There was uncertainty about
the role of cord blood as an appropriate cell source (53.2% agree) and
the utility of reduced intensity alloHCT (RIC alloHCT) (41%
agree). The strongest agreement was on the role of AlloHCT in Phil-
adelphia positive ALL (98% agree).
Conclusions: In Canada, there is substantial disagreement about in-
dications for alloHCT in adult ALL in CR1. Respondents felt that
alloHCTwas particularly helpful in high-risk patients, contradicting
the results of the MRC/ECOG study. The t(9;22) was felt to be
a strong indication for transplant. Consensus was lacking on the
use of cord blood or RIC alloHCT. Although MRD testing was
thought to be a useful guide to planning therapy, it was not widely
available. Equipoise exists on the role of alloHCT in CR1 in ALL,
suggesting further trials in this area are needed.
1 – Goldstone et al, Blood, 2008.
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SELF COLLECTION OF NASAL SWABS FOR DIAGNOSIS OF RESPIRATORY
VIRUSES IN IMMUNOCOMPETENT VOLUNTEERS AND HEMATOPOIETIC
STEM CELL TRANSPLANT (HCT) RECIPIENTS
Campbell, A.P.1,2,3, Kuypers, J.2,3, Callais, C.L.3, Guthrie, K.A.3,
Englund, J.A.1,2,3, Boeckh, M.2,3 1Seattle Children’s Hospital, Seattle,
WA; 2University of Washington, Seattle, WA; 3Fred Hutchinson Cancer
Research Center, Seattle, WA
Background:We previously developed a method for self collection
of nasal swab samples and demonstrated that self-collected swabs
were sensitive (sensitivity 96%) compared with staff-collected nasal
washes (sensitivity 88%) for detection of respiratory viruses (RVs)
by PCR in 152 collections from immunocompetent volunteers
with new upper respiratory infections (URIs). Our self-collection
method employed saline spray delivered by a metered spray bottle
and a polyurethane foam swab, but many current protocols advocate
use of dry respiratory swabs. In the present study, we compare collec-
tion of swabs with and without use of saline spray in both immuno-
competent volunteers and HCT recipients.
Methods: Immunocompetent volunteers with new URI completed
a symptom survey and performed self collection in one naris using
saline spray and a polyurethane foam swab (‘‘wet’’), and in the oppo-
site naris using a swab alone (‘‘dry’’). HCT recipients with a docu-
mented virologically-positive URI completed a symptom survey
and collection procedure within 1 week of initial diagnosis; these
subjects were followed weekly as feasible until negative. Swabs
Table. Number of virus detections, average PCR CT values, and sensitivity of PCR for detection in wet versus dry swab collections
Negative
Swab Pairs
Virus
Detections:
Positive
Wet & Dry
Virus
Detections:
Positive Wet,
Negative Dry
Virus
Detections:
Positive Dry,
Negative Wet % Sensitivity
N N (Ave. CT Value Wet; Dry) N (Ave. CT Value) N (Ave. CT Value) Wet Swabs Dry Swabs
Immunocompetent Controls (N 5 106
collections)
All virus detections# 28 78 (27.1; 27.2) 10 (34.6) 3 (34.3) 97 89
+ Rhinorrhea (n 5 83)* 18 65 (26.8; 26.8) 7a (35.4) 3b (34.3) 96 91
2 Rhinorrhea (n 5 22)* 9 13 (28.9; 29.4) 3c (32.8) 0 100 81
HCT Patients (N 5 105 collections)
All virus detections# 20 69 (28.2; 28.4) 14 (33.5) 12 (32.8) 87 85
+ Rhinorrhea (n 5 66) 9 48 (27.5; 27.8) 8d (32.5) 7e (33.0) 89 87
2 Rhinorrhea (n 5 39) 11 21 (29.9; 29.7) 6f (35.9) 5g (32.4) 84 81
#Total N is greater than number of paired swab collections because of multiple virus detections in some swabs.
*1 survey was blank for rhinorrhea and omitted. Discordant virus detections.
aAdenovirus (AdV) x3, parainfluenza (PIV) 3, PIV4, coronavirus (HCoV)/rhinovirus (HRV) co-infection.
bHRV x2, bocavirus.
cInfluenza A, AdV, HCoV.
drespiratory syncytial virus (RSV) x2, PIV3 x2, HRV x2, AdV, HCoV.
ePIV3, PIV1, HCoV, HRV x4.
fRSV, PIV3 x2, HCoV x2, AdV.
gRSV x2, HRV x3.
S346 Poster Session IIwere stored at ambient temperature, and PCR testing was performed
for 12 RVs (positive value 5 threshold cycle [CT]\ 40).
Results: Samples were collected during 106 URIs in 70 immuno-
competent persons; 3 subjects were \ 6 yo (parent performed).
Counting all positive respiratory virus detections as true positives,
sensitivity was 88/91 5 97% for wet swabs and 81/91 5 91% for
dry (Table). Among 30 HCT recipients aged . 6 yo, 105 paired
samples were collected during 30 URIs (median 3 samples/patient,
range 1-9). Sensitivity was 83/955 87% for wet swabs and 81/955
85% for dry. In both populations, discordant results were associated
with higher averageCT values (i.e., lower viral load), and discordance
was highest in samples collected fromHCT recipients. Dry swabs, in
particular, appeared to perform better in subjects with rhinorrhea
than without. A subset of 73 immunocompetent subjects rated the
self collected swabs simple (96%) and comfortable (88%); no epi-
staxis occurred with any collection.
Conclusion: Ourmethod of foam swab self-collection of nasal secre-
tions is simple, comfortable, and safe amongHCT recipients. Discor-
dance between wet and dry swabs increased with lower viral load.
Overall, thewet swabappeared to increase sensitivity for respiratory vi-
ral detection in both immunocompetent subjects and HCT patients.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR SICKLE CELL ANEMIA
(SCA) AT MSKCC: A SINGLE INSTITUTION SERIES
Anur, P., Sklar, C., Kernan, N.A., Prockop, S.E., Scaradavou, A.,
Small, T.N., O’Reilly, R.J., Boulad, F. Memorial Sloan Kettering Cancer
Center, New York, NY
Background: Allogeneic hematopoietic stem cell transplantation
(SCT) is the only proven cure for children with sickle cell anemia.
SCT is considered for high risk patients with SCA who have an
HLA-matched sibling donor.
Methods: We reviewed medical records of 13 children (1.4 -19.2
years, 8 females and 5 males) who received allogeneic SCT from
matched sibling donors from 1994-2010 for SCA at Memorial
Sloan-Kettering Cancer Center (MSKCC).
Results: Indications for HSCTwere: stroke (n5 3), acute chest syn-
drome (n 5 6), multiple vaso-occlusive crises (n 5 10), and allo-im-
munization (n 5 3); nine patients had more than one risk factor.
Donors were heterozygous for sickle cell (n5 9) or with normal he-
moglobin (n 5 4). All patients received marrow grafts while one pa-
tient received combined marrow and cord blood grafts. Nine
patients received standard cytoreduction with Busulfan/Cyclophos-
phamide. Three other regimens were used in an attempt to decrease
toxicity and improve chimerism. They were Busulfan/Fludarabine
(n 5 2), Busulfan/Cyclophosphamide/Fludarabine (n 5 1) andBusulfan/Melphalan/Fludarabine (n 5 1). GvHD prophylaxis in-
cluded cyclosporine (CSA) and methotrexate (MTX) (n 5 9), tacro-
limus and MTX (n 5 2), or other (n 5 2). All 13 patients engrafted.
With a median follow-up of 10.2 years (range 0.9-17.6 years), twelve
of 13 patients are alive and well. One patient died of interstitial pneu-
monitis on day +77 post SCT. No patient developed acute GvHD.
Two patients developed de-novo limited chronic GvHD, which re-
solved. Donor chimerism included 100% (n 5 5), 76-97% (n 5 5)
while two patients recipients of Bu/Cy regimen had 35% and 50%
donor cells. Six of 7 evaluable patients showed evidence of splenic
function recovery post transplant. Late effects analysis included eval-
uation of gonadal function revealing 6 of 8 females with ovarian
dysfunction.
Conclusions: This single institution based SCT series for SCA is
consistent with multi-institutional series results, showing a very
good outcome following Busulfan based myeloablative regimen. Fu-
ture directions include the improvement of donor chimerism, and
the late effects of treatment including that of gonadal function.
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FAVORABLE OUTCOMES IN ELDERLY AND HIGH-RISK PATIENTS WITH
AML AND MDS FOLLOWING T-CELL DEPLETED REDUCED INTENSITY
CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION
Nicholson, E.1, Mackinnon, S.1, Thomson, K.J.2, Sudak, J.1,
Fielding, A.K.1, Kottaridis, P.1, Peggs, K.S.2, Morris, E.C.2,
Chakraverty, R.1 1Royal Free Hospital, London, United Kingdom;
2University College Hospital, London, United Kingdom
For patients with high-risk acute myeloid leukemia(AML),mye-
loablative conditioning(MAC) followed by allogeneic hematopoietic
stem cell transplantation(allo-HSCT) offers the best chance of long-
term disease free survival.Retrospective analysis comparing reduced
intensity conditioning(RIC) and MAC suggest that early OS and
PFS rates are comparable where increased relapse rate(RR) is offset
by reduced non-relapse mortality(NRM).In AML patients receiving
a RIC regimen,very high RR has been observed in patients with poor
risk cytogenetics.We analyzed outcomes of 70 consecutive adult pa-
tients with AML or MDS(CR1 or CR2 at time of allo-HSCT) who
received Fludarabine(150mg/m2),Melphalan(140mg/m2) Alemtu-
zumab(CAMPATH)(20-100mg)(FMC) RIC regimen.Median age
at transplant was 56 yrs(range 17-70).29 had a HLA identical sibling
donor and 41 an unrelated donor(29 matched;12 mismatched).Stem
cell source was PBSC in 66 and BM in 4 patients.43 patients were in
CR1 and 27 were in CR2.Median follow up of live patients was 32
months(range 12-119).OS and PFS at 3 yrs was 55% and
53%.100-day and 3-yr NRM rates were 10% and 24%.3-yr
RR was 25% and median time to relapse was 6.2 months (range
